

OBNM Formulary Council – March 14, 2012- Meeting Minutes

PRESENT: Kevin Wilson, ND; John Block, PhD.; Ann Blair, PhD.; Patrick Chapman, ND; Natalie Gustafson, PharmD; Dohn Kruschwitz, MD; Anne Walsh, Executive Director

EXCUSED: Joseph Lassiter, PharmD

Opened at 9:35am

September 21, 2011 Minutes: With a few minor changes, the minutes from the September 21, 2011 meeting were approved.

Drug Review: *Nitrous Oxide:* The intent of the request is for use when doing a colonoscopy; this training is not within the scope of the FC scope. After discussion and review of the material provided the FC members voted to recommend the inclusion of nitrous oxide to the classification 850-060-0226(8) Central Nervous System Agents (f)(B)(i). Dr. Block made a motion to recommend Nitrous Oxide to 850-060-0226, Dr. Chapman seconded the motion; Dr. Wilson voted “nay”; all other members voted in agreement to approve for inclusion to the compendium. Dr. Wilson’s vote was to make sure Board knows there may be some concerns related to using nitrous oxide for colonoscopy if appropriate training is not first obtained.

IM Injection of antibiotics is within the scope of practice. No action needs to be taken by the Board.

Ozone: Dr. Wilson attended a seminar/training for ozone therapy in October and reported to the FC. He found the course very informative and although he saw some possible benefits to ozone therapy with the appropriate training, he was not confident that it should be added to the formulary.

A motion was presented to table the discussion on ozone therapy, since there is still uncertainty in the certification of the generators and training. Any further discussion on ozone therapy will be tabled until a future meeting.

Administrative Rules: Discussion that 850-060-0225 (Alpha List) is out-dated; however, kept in case something that was on the list prior to the classification expansion. The alphabetical list is frustrating to many pharmacists. There was discussion on adding language to ask NDS to use the classification rules to find Board will ask OANP to request a “exclusionary” formulary instead of the “inclusionary” rule. Dr. Wilson will ask the OANP if they can move forward this legislation; the OBNM will be asked to support this. P. Chapman moved that the OBNM support the OANP if they take forward legislation to the above intention.

Dr. Wilson had a preliminary discussion on the restriction of *Suboxone* prescribing by NDs, because a federal law only allows MD and DOs to prescribe. Several drugs require a category “X” and ND’s cannot apply for this. It seems the pain commission may be good as an advocate with the national legislation level. This discussion will be continued at a future meeting.

Medical Marijuana – Dr. Wilson also spoke to the use of medical marijuana. Pain Society of Oregon has no position at this time. Marinol is on the formulary; as it is a Class III.

The fall meeting was tentatively set for September 19, 2012, to start at 9:30am.

The FC meeting was adjourned at 11:30am

.....

OBNM Meeting Minutes – April 9, 2012

Formulary Update – A Formulary Council meeting was held on March 14, 2012. P. Chapman attended as the Board’s representative. Aside from the recommendation regarding nitrous oxide being added to the formulary classification list, there was a discussion about requesting the OANP reinstate the efforts to change the formulary from inclusionary to exclusionary to make it more clearly understandable for doctors, pharmacists, and the public.

OAR 850-060-0226 – The Formulary Council, through the Board’s representative, P. Chapman, recommended adding nitrous oxide to the formulary classification list. S. Ohgushi moved to initiate a rule change to amend the formulary to correct a numbering error and add nitrous oxide to the classification list, D. Adkins seconded and the motion passed unanimously.

DRAFT